Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
What dose would you give for LRC for a PEcoma (perivascular epitheliod cell tumor) of the anal canal?
Related Questions
Given the results of ESOPEC from ASCO 2024, for which patients with resectable esophageal adenocarcinoma would you favor neoadjuvant chemoradiation?
In which patients with early stage rectal cancer treated according to the PROSPECT paradigm do you recommend adjuvant chemotherapy?
Is there data to support worse surgical outcomes in short course RT followed by surgery vs. long course chemoradiation followed by surgery in rectal cancer?
How do you manage persistent rectal bleeding in the setting of rectal adenocarcinoma in a treatment-naive patient?
What volumes would you cover preoperatively for a young patient with a history of proctocolectomy with J-pouch for FAP now with an adenocarcinoma at the ileoanal junction?
What is your approach to TNT sequencing for locally advanced rectal primaries with low volume metastatic disease to liver?
Are you using vaginal dilators during treatment of rectal cancer to spare anterior vaginal wall, or are you reserving this for anal cancers?
Would you offer chemoRT to a colon cancer case with a resected polyp with positive margins if the patient wishes to avoid surgery?
Do you use different dose constraints for large bowel vs. small bowel?
When a patient with pancreatic cancer received neoadjuvant chemo + chemo-RT, how do you manage an in-field, post operative positive margin?
